CD146 is a potential immunotarget for neuroblastoma.
Animals
Antibodies
/ therapeutic use
Apoptosis
CD146 Antigen
/ antagonists & inhibitors
Cell Line, Tumor
Cell Survival
Focal Adhesion Kinase 1
/ metabolism
Focal Adhesion Protein-Tyrosine Kinases
/ metabolism
Gene Knockdown Techniques
Heterografts
Humans
Mice
Molecular Targeted Therapy
/ methods
NF-kappa B
/ metabolism
Neoplasm Recurrence, Local
Neoplasm Transplantation
Neuroblastoma
/ metabolism
Prognosis
RNA, Small Interfering
/ therapeutic use
Signal Transduction
Spheroids, Cellular
Transduction, Genetic
/ methods
CD146
antibody
apoptosis
focal adhesion kinase
neuroblastoma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
13
08
2021
received:
27
05
2021
accepted:
26
08
2021
pubmed:
1
9
2021
medline:
24
11
2021
entrez:
31
8
2021
Statut:
ppublish
Résumé
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to arise from neural crest-derived immature cells. The prognosis of patients with high-risk or recurrent/refractory neuroblastoma remains quite poor despite intensive multimodality therapy; therefore, novel therapeutic interventions are required. We examined the expression of a cell adhesion molecule CD146 (melanoma cell adhesion molecule [MCAM]) by neuroblastoma cell lines and in clinical samples and investigated the anti-tumor effects of CD146-targeting treatment for neuroblastoma cells both in vitro and in vivo. CD146 is expressed by 4 cell lines and by most of primary tumors at any stage. Short hairpin RNA-mediated knockdown of CD146, or treatment with an anti-CD146 polyclonal antibody, effectively inhibited growth of neuroblastoma cells both in vitro and in vivo, principally due to increased apoptosis via the focal adhesion kinase and/or nuclear factor-kappa B signaling pathway. Furthermore, the anti-CD146 polyclonal antibody markedly inhibited tumor growth in immunodeficient mice inoculated with primary neuroblastoma cells. In conclusion, CD146 represents a promising therapeutic target for neuroblastoma.
Identifiants
pubmed: 34464480
doi: 10.1111/cas.15124
pmc: PMC8586675
doi:
Substances chimiques
Antibodies
0
CD146 Antigen
0
NF-kappa B
0
RNA, Small Interfering
0
Focal Adhesion Kinase 1
EC 2.7.10.2
Focal Adhesion Protein-Tyrosine Kinases
EC 2.7.10.2
PTK2 protein, human
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4617-4626Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 19ck0106468h0001
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Oncotarget. 2016 Nov 18;8(32):52193-52210
pubmed: 28881723
Mod Pathol. 1998 Nov;11(11):1098-106
pubmed: 9831208
Int J Cancer. 2009 Mar 15;124(6):1301-11
pubmed: 19065652
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Cancer Sci. 2021 Nov;112(11):4617-4626
pubmed: 34464480
Int J Cancer. 2015 Mar 1;136(5):E252-61
pubmed: 25220031
PLoS One. 2015 Feb 19;10(2):e0117953
pubmed: 25695505
J Clin Invest. 2017 Jun 30;127(7):2815-2828
pubmed: 28530640
Cancer Res. 2002 Sep 1;62(17):5106-14
pubmed: 12208768
J Cell Biol. 1996 Aug;134(3):793-9
pubmed: 8707856
Cancer Lett. 2013 Apr 28;330(2):150-62
pubmed: 23266426
Int J Cancer. 2020 Sep 15;147(6):1666-1679
pubmed: 32022257
Blood. 2014 Apr 10;123(15):2293-301
pubmed: 24578502
Oncogene. 2007 Nov 22;26(53):7401-13
pubmed: 17533365
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
J Cell Physiol. 2004 Mar;198(3):377-87
pubmed: 14755543
Pediatr Blood Cancer. 2011 Oct;57(4):629-35
pubmed: 21319289
Oncotarget. 2015 Nov 3;6(34):35247-62
pubmed: 26497213
Oncogene. 2016 Oct 6;35(40):5317-5327
pubmed: 27041577
Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1026-1033
pubmed: 31070478
J Biol Chem. 1998 Oct 9;273(41):26852-6
pubmed: 9756930
Clin Cancer Res. 2003 Dec 15;9(17):6560-6
pubmed: 14695161
Clin Cancer Res. 2008 Jun 1;14(11):3299-305
pubmed: 18519756
Annu Rev Cell Dev Biol. 2006;22:267-86
pubmed: 16803431
Int J Dev Biol. 2002 Mar;46(2):263-6
pubmed: 11934156
Dev Dyn. 2015 Mar;244(3):311-22
pubmed: 25382669
Oncol Lett. 2017 Feb;13(2):912-920
pubmed: 28356978
EBioMedicine. 2015 Nov 10;2(12):1923-31
pubmed: 26844271
J Clin Oncol. 2016 Jul 20;34(21):2443-51
pubmed: 27069083
Cytogenet Cell Genet. 1999;87(3-4):258
pubmed: 10702685
Front Oncol. 2012 Dec 17;2:194
pubmed: 23251904
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer. 2014 Aug 15;120(16):2497-506
pubmed: 24853691
J Clin Oncol. 2010 Nov 20;28(33):4969-75
pubmed: 20921469
Int J Cancer. 2015 Jul 1;137(1):50-60
pubmed: 25449773
Oncogene. 1999 Sep 2;18(35):4948-57
pubmed: 10490829
Cancer. 1999 Jul 15;86(2):364-72
pubmed: 10421273
Cancer Lett. 2013 Apr 30;331(1):115-21
pubmed: 23268333
Neuroimmunomodulation. 1998 Sep-Oct;5(5):270-6
pubmed: 9730695
J Clin Oncol. 2011 Aug 20;29(24):3286-92
pubmed: 21768459
PLoS One. 2013 Sep 10;8(9):e74124
pubmed: 24040184
Mol Cancer Ther. 2006 Nov;5(11):2872-8
pubmed: 17121934
N Engl J Med. 2010 Sep 30;363(14):1324-34
pubmed: 20879881
Cancer Res. 1991 Jan 1;51(1):144-9
pubmed: 1988079
Blood. 2003 Jul 1;102(1):184-91
pubmed: 12609848
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250
pubmed: 31186061
J Clin Oncol. 1993 Aug;11(8):1466-77
pubmed: 8336186
Clin Cancer Res. 2005 May 1;11(9):3280-7
pubmed: 15867224
J Pathol. 1999 Sep;189(1):4-11
pubmed: 10451481
J Biol Chem. 2007 Apr 27;282(17):12503-16
pubmed: 17327229